{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:12:47Z","timestamp":1793038367258,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.amjmed.2021.04.024","type":"journal-article","created":{"date-parts":[[2021,5,23]],"date-time":"2021-05-23T11:35:17Z","timestamp":1621769717000},"page":"1076-1084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Comprehensive Cardiovascular-Renal-Metabolic Risk Reduction Approach to Patients with Type 2 Diabetes Mellitus"],"prefix":"10.1016","volume":"134","author":[{"given":"Neha J.","family":"Pagidipati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Deedwania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2021.04.024_bib0001","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc20-S010","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0002","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/dci18-0007","article-title":"Economic costs of diabetes in the U.S. in 2017","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0003","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Seshasai","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0004","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","article-title":"Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations","volume":"133","author":"Low Wang","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0006","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2011.861","article-title":"Temporal trends in the prevalence of diabetic kidney disease in the United States","volume":"305","author":"de Boer","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0007","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0008","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0009","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1464-5491.2008.02640.x","article-title":"Is diabetes a coronary risk equivalent? Systematic review and meta-analysis","volume":"26","author":"Bulugahapitiya","year":"2009","journal-title":"Diabet Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11606-015-3556-3","article-title":"Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events","volume":"31","author":"Rana","year":"2016","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0011","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJM200004063421408","article-title":"Coronary heart disease in patients with diabetes","volume":"342","author":"Haffner","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0012","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/eurheartj\/ehy036","article-title":"Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke","volume":"39","author":"Echouffo-Tcheugui","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0013","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1161\/STROKEAHA.111.621649","article-title":"Diabetes and poor outcomes within 6 months after acute ischemic stroke: the China National Stroke Registry","volume":"42","author":"Jia","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0014","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","article-title":"Role of diabetes in congestive heart failure: the Framingham study","volume":"34","author":"Kannel","year":"1974","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0015","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.2337\/diacare.26.10.2949","article-title":"Diabetic cardiomyopathy","volume":"26","author":"Bell","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0016","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2213-8587(14)70031-2","article-title":"Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored","volume":"2","author":"McMurray","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0017","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2337\/diacare.27.8.1879","article-title":"The incidence of congestive heart failure in type 2 diabetes: an update","volume":"27","author":"Nichols","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0018","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1007\/s00125-018-4700-5","article-title":"Excess risk of hospitalisation for heart failure among people with type 2 diabetes","volume":"61","author":"Rosengren","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0019","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2337\/dc17-0697","article-title":"Prognostic impact of diabetes on long-term survival outcomes in patients with heart failure: a meta-analysis","volume":"40","author":"Dauriz","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0020","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","article-title":"Epidemiology of peripheral artery disease","volume":"116","author":"Criqui","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0021","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jacc.2005.09.065","article-title":"Peripheral arterial disease in patients with diabetes","volume":"47","author":"Marso","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0022","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1161\/ATVBAHA.120.314595","article-title":"Epidemiology and risk of amputation in patients with diabetes mellitus and peripheral artery disease","volume":"40","author":"Barnes","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0023","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.2337\/dc20-S011","article-title":"11. Microvascular complications and foot care: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0024","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.semnephrol.2018.02.003","article-title":"Cardiovascular disease and diabetic kidney disease","volume":"38","author":"Maqbool","year":"2018","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0026","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1097\/01.ASN.0000019641.41496.1E","article-title":"Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study","volume":"13","author":"Longenecker","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0027","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.2337\/dc20-S005","article-title":"5. Facilitating behavior change and well-being to improve health outcomes: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0028","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.2337\/dc20-S008","article-title":"8. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0029","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2337\/dc16-1728","article-title":"Physical activity\/exercise and diabetes: a position statement of the American Diabetes Association","volume":"39","author":"Colberg","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0030","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0031","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0032","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","article-title":"Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis","volume":"313","author":"Emdin","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0033","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0034","doi-asserted-by":"crossref","first-page":"i717","DOI":"10.1136\/bmj.i717","article-title":"Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses","volume":"352","author":"Brunstrom","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0036","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0037","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0038","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.hlc.2010.07.013","article-title":"Intensive glucose control and cardiovascular outcomes in type 2 diabetes","volume":"20","author":"Macisaac","year":"2011","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0039","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0040","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S2213-8587(17)30104-3","article-title":"Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials","volume":"5","author":"Zoungas","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0041","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Group","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0042","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0043","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1161\/CIRCULATIONAHA.117.027252","article-title":"Secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus: international insights from the TECOS Trial (trial evaluating cardiovascular outcomes with sitagliptin)","volume":"136","author":"Pagidipati","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0044","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)07368-1","article-title":"Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study","volume":"353","author":"Gaede","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0045","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0046","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","article-title":"Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the STENO-2 randomised trial","volume":"59","author":"Gaede","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0047","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0048","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0049","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0050","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0051","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0052","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0053","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0054","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0055","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0056","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0057","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0058","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0059","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0060","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0061","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ckj\/sfy090","article-title":"The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study","volume":"11","author":"Herrington","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0062","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ejhf.1596","article-title":"Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0063","unstructured":"ClinicalTrials.gov, U.S. National Library of Medicine. Dapagliflozin evaluation to improve the lives of patients with preserved ejection fraction heart failure (DELIVER). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03619213. Accessed June 9, 2021."},{"key":"10.1016\/j.amjmed.2021.04.024_bib0064","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/2042018814559725","article-title":"GLP-1 receptor agonists: a review of head-to-head clinical studies","volume":"6","author":"Trujillo","year":"2015","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0065","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0066","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","article-title":"Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial","volume":"6","author":"Muskiet","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0067","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0068","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0069","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0070","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0071","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2337\/dc19-1065","article-title":"Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial","volume":"43","author":"Bethel","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0072","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0073","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0074","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0075","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0076","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0077","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0078","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0079","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0080","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"issue":"Suppl 2","key":"10.1016\/j.amjmed.2021.04.024_bib0081","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.2337\/dcS13-2015","article-title":"GLP-1 effects on islets: hormonal, neuronal, or paracrine?","volume":"36","author":"Donath","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0082","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1161\/CIR.0000000000000920","article-title":"Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association","volume":"142","author":"Rangaswami","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0083","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/1479164113496828","article-title":"Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: comparison by prevalent cardiovascular disease status","volume":"10","author":"Wong","year":"2013","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.amjmed.2021.04.024_bib0084","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016835","article-title":"Gaps in evidence-based therapy use in insured patients in the united states with type 2 diabetes mellitus and atherosclerotic cardiovascular disease","volume":"10","author":"Nelson","year":"2021","journal-title":"J Am Heart Assoc"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293432100317X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293432100317X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:23:29Z","timestamp":1757582609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293432100317X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":84,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S000293432100317X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2021.04.024","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Comprehensive Cardiovascular-Renal-Metabolic Risk Reduction Approach to Patients with Type 2 Diabetes Mellitus","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2021.04.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}